Profile data is unavailable for this security.
About the company
AbCellera Biologics Inc. is focused on the development of antibody-based drugs and is committed to improving discovery and development. It is engaged in antibody discovery and development engine is specifically designed to break the barriers of conventional discovery. It provides biotech and pharmaceutical companies with an advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development. The Company uses the engine to both work with partners to build a large and diversified portfolio of royalty stakes in antibody drugs and to develop its own pipeline of antibody drugs. The Company partners with companies of all sizes, from biotechnology companies to pharmaceutical companies-propelling programs to the clinic, together. It generates a range of diverse antibodies with immunization strategies and single-cell screening.
- Revenue in USD (TTM)35.79m
- Net income in USD-146.90m
- Incorporated2012
- Employees586.00
- LocationAbcellera Biologics Inc2215 Yukon StreetVANCOUVER V5Y 0A1CanadaCAN
- Phone+1 (604) 559-9005
- Websitehttps://www.abcellera.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharvaris NV | 0.00 | -115.20m | 1.02bn | 82.00 | -- | 2.62 | -- | -- | -2.58 | -2.58 | 0.00 | 7.24 | 0.00 | -- | -- | 0.00 | -40.45 | -36.09 | -43.50 | -38.27 | -- | -- | -- | -- | -- | -127.47 | 0.0005 | -- | -- | -- | -32.15 | -- | -- | -- |
| Arcturus Therapeutics Holdings Inc | 124.53m | -107.30m | 1.05bn | 180.00 | -- | 3.96 | -- | 8.39 | -4.02 | -4.02 | 4.66 | 9.81 | 0.2799 | -- | 2.08 | 691,811.10 | -24.12 | -19.66 | -31.37 | -24.90 | -- | -- | -86.16 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
| Cassava Sciences Inc | 0.00 | -47.90m | 1.06bn | 29.00 | -- | 12.12 | -- | -- | -1.17 | -1.17 | 0.00 | 1.82 | 0.00 | -- | -- | 0.00 | -25.63 | -30.74 | -33.88 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
| Enliven Therapeutics Inc | 0.00 | -79.60m | 1.06bn | 46.00 | -- | 3.32 | -- | -- | -1.93 | -1.93 | 0.00 | 6.79 | 0.00 | -- | -- | 0.00 | -24.66 | -42.26 | -26.11 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
| Collegium Pharmaceutical Inc | 566.92m | 93.29m | 1.08bn | 197.00 | 16.10 | 4.88 | 4.52 | 1.91 | 2.06 | 2.06 | 12.06 | 6.79 | 0.4869 | 7.07 | 3.20 | 2,877,782.00 | 8.01 | 2.79 | 12.70 | 4.80 | 60.01 | 50.88 | 16.46 | 5.16 | 1.14 | 3.10 | 0.7372 | 0.00 | 22.17 | 15.11 | 292.60 | -- | -54.77 | -- |
| Prothena Corporation PLC | 89.25m | -172.40m | 1.12bn | 173.00 | -- | 2.23 | -- | 12.54 | -3.25 | -3.25 | 1.63 | 9.35 | 0.1308 | -- | -- | 515,901.70 | -25.26 | -14.20 | -27.09 | -15.11 | -- | -- | -193.17 | -111.02 | -- | -- | 0.00 | -- | 69.50 | 148.98 | -25.72 | -- | 9.71 | -- |
| Mirum Pharmaceuticals Inc | 224.00m | -158.56m | 1.13bn | 278.00 | -- | 4.82 | -- | 5.06 | -3.82 | -3.82 | 5.19 | 4.99 | 0.4546 | 4.24 | 5.62 | 848,477.30 | -32.18 | -38.93 | -38.17 | -44.88 | 73.26 | -- | -70.79 | -190.71 | 3.47 | -- | 0.5667 | -- | 141.85 | -- | -20.45 | -- | 21.81 | -- |
| AbCellera Biologics Inc | 35.79m | -146.90m | 1.15bn | 586.00 | -- | 1.02 | -- | 32.21 | -0.5056 | -0.5056 | 0.1232 | 3.85 | 0.0242 | -- | 1.32 | 61,071.67 | -9.92 | 6.08 | -10.62 | 6.67 | -- | -- | -410.47 | 24.69 | 7.75 | -- | 0.00 | 0.00 | -92.17 | 33.91 | -192.35 | -- | 70.96 | -- |
| Day One Biopharmaceuticals Inc | 0.00 | -208.94m | 1.16bn | 174.00 | -- | 3.91 | -- | -- | -2.50 | -2.50 | 0.00 | 3.40 | 0.00 | -- | -- | 0.00 | -64.27 | -- | -69.93 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.87 | -- | -- | -- |
| Ginkgo Bioworks Holdings Inc | 208.70m | -853.81m | 1.17bn | 1.22k | -- | 1.09 | -- | 5.60 | -0.4347 | -0.4347 | 0.1061 | 0.4855 | 0.1044 | -- | 3.82 | 171,344.00 | -42.70 | -- | -46.94 | -- | 80.43 | -- | -409.12 | -- | -- | -- | 0.00 | -- | -47.36 | -- | 57.58 | -- | -- | -- |
| 4D Molecular Therapeutics Inc | 20.45m | -104.56m | 1.24bn | 171.00 | -- | 2.04 | -- | 60.59 | -2.36 | -2.36 | 0.4841 | 11.74 | 0.0468 | -- | -- | 139,136.00 | -23.93 | -32.67 | -24.71 | -34.90 | -- | -- | -511.20 | -617.15 | -- | -- | 0.00 | -- | 562.29 | 7.96 | 6.19 | -- | 46.26 | -- |
| Tarsus Pharmaceuticals Inc | 42.56m | -148.21m | 1.25bn | 244.00 | -- | 4.52 | -- | 29.26 | -4.72 | -4.72 | 1.35 | 7.29 | 0.1519 | -- | 2.63 | 174,430.30 | -52.88 | -31.56 | -58.73 | -33.82 | 92.37 | -- | -348.22 | -242.59 | 7.92 | -- | 0.0981 | -- | -32.42 | -- | -118.86 | -- | 279.39 | -- |
| MannKind Corp | 224.60m | 8.49m | 1.27bn | 414.00 | 199.32 | -- | 94.55 | 5.66 | 0.0234 | 0.0234 | 0.7589 | -0.8492 | 0.5766 | 2.69 | 11.34 | 542,509.70 | 2.18 | -26.07 | 2.84 | -37.80 | 70.99 | 59.68 | 3.78 | -57.61 | 3.57 | 1.50 | 1.80 | -- | 99.42 | 48.17 | 86.34 | -- | 160.47 | -- |
Data as of May 31 2024. Currency figures normalised to Abcellera Biologics Inc's reporting currency: US Dollar USD
30.02%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 31 Mar 2024 | 27.53m | 9.40% |
| Baillie Gifford & Co.as of 31 Mar 2024 | 23.18m | 7.92% |
| Voya Investment Management Co. LLCas of 31 Mar 2024 | 10.63m | 3.63% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 8.35m | 2.85% |
| Credit Suisse Asset Management (Schweiz) AGas of 31 Mar 2024 | 4.54m | 1.55% |
| ArrowMark Colorado Holdings LLCas of 31 Mar 2024 | 4.11m | 1.40% |
| Hermes Investment Management Ltd.as of 31 Mar 2024 | 2.74m | 0.94% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.44m | 0.83% |
| Casdin Capital LLCas of 31 Mar 2024 | 2.36m | 0.81% |
| Lazard Asset Management LLCas of 31 Mar 2024 | 2.02m | 0.69% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
